Dupont Capital Management Corp trimmed its holdings in Bioverativ Inc (NASDAQ:BIVV) by 8.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 18,900 shares of the biotechnology company’s stock after selling 1,800 shares during the quarter. Dupont Capital Management Corp’s holdings in Bioverativ were worth $1,019,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. BP PLC purchased a new position in Bioverativ in the third quarter worth approximately $799,000. Whittier Trust Co. of Nevada Inc. purchased a new position in Bioverativ in the third quarter worth approximately $293,000. Catalyst Capital Advisors LLC purchased a new position in Bioverativ in the third quarter worth approximately $5,707,000. American Century Companies Inc. purchased a new position in shares of Bioverativ during the third quarter worth $48,168,000. Finally, Stifel Financial Corp purchased a new position in shares of Bioverativ during the third quarter worth $3,576,000. Institutional investors own 95.14% of the company’s stock.

BIVV has been the subject of several research analyst reports. Royal Bank of Canada raised their price target on Bioverativ to $68.00 and gave the stock a “market perform” rating in a research report on Thursday, January 18th. Zacks Investment Research lowered Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Jefferies Group raised their price target on Bioverativ to $79.00 and gave the stock a “buy” rating in a research report on Thursday, January 18th. Raymond James Financial lowered Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 23rd. Finally, Credit Suisse Group restated a “neutral” rating and set a $65.00 price target on shares of Bioverativ in a research report on Thursday, January 18th. Thirteen analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Bioverativ has an average rating of “Hold” and a consensus target price of $63.15.

Shares of Bioverativ Inc (NASDAQ:BIVV) opened at $103.26 on Thursday. Bioverativ Inc has a 52 week low of $41.88 and a 52 week high of $104.30.

TRADEMARK VIOLATION NOTICE: “Dupont Capital Management Corp Has $1.02 Million Position in Bioverativ Inc (BIVV)” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://theolympiareport.com/2018/02/08/dupont-capital-management-corp-has-1-02-million-position-in-bioverativ-inc-bivv.html.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.